Cencora, Inc. (NYSE:COR) Shares Sold by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 64.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,504 shares of the company's stock after selling 8,242 shares during the period. Union Bancaire Privee UBP SA's holdings in Cencora were worth $1,234,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. purchased a new position in shares of Cencora in the fourth quarter valued at $205,000. Savant Capital LLC boosted its position in shares of Cencora by 4.1% in the 4th quarter. Savant Capital LLC now owns 7,312 shares of the company's stock worth $1,643,000 after buying an additional 291 shares in the last quarter. Certuity LLC acquired a new stake in Cencora in the 4th quarter valued at about $295,000. Kentucky Trust Co purchased a new position in Cencora during the 4th quarter valued at about $33,000. Finally, MGB Wealth Management LLC raised its position in Cencora by 2.7% during the fourth quarter. MGB Wealth Management LLC now owns 4,759 shares of the company's stock worth $1,069,000 after acquiring an additional 124 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 0.0%

NYSE COR traded up $0.08 during trading hours on Friday, hitting $295.12. 966,888 shares of the company's stock were exchanged, compared to its average volume of 1,526,444. The business's 50 day moving average is $287.24 and its 200-day moving average is $261.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35. The firm has a market capitalization of $57.20 billion, a P/E ratio of 41.98, a price-to-earnings-growth ratio of 1.31 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the prior year, the firm posted $3.80 EPS. The company's revenue was up 10.3% on a year-over-year basis. As a group, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,253 shares of company stock worth $10,582,297 in the last quarter. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

COR has been the topic of several research reports. Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus price target of $306.91.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.